TERN
Terns Pharmaceuticals, Inc.
Key Financials
Operating Income
$-110124000
↓ 8.1%
Net Income
$-96207000
↓ 8.3%
Total Assets
$1.0B
↑ 181.7%
EPS (Diluted)
$-1.03
↑ 8.0%
Shareholders' Equity
$1.0B
↑ 191.0%
Long-term Debt
$0.00
↓ 100.0%
Total Liabilities
$18.6M
↑ 2.7%
Cash & Equivalents
$524.7M
↑ 225.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SC 14D9 | 4/7/2026 | View on SEC |
| SC TO-T | 4/7/2026 | View on SEC |
| 4 | 4/2/2026 | View on SEC |
| S-8 | 3/30/2026 | View on SEC |
| 10-K | 3/30/2026 | View on SEC |
| SCHEDULE 13G/A | 3/27/2026 | View on SEC |
| SC TO-C | 3/26/2026 | View on SEC |
| SC14D9C | 3/25/2026 | View on SEC |
| SC TO-C | 3/25/2026 | View on SEC |
| SC14D9C | 3/25/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | TERN |
| Company Name | Terns Pharmaceuticals, Inc. |
| CIK | 1831363 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 650-525-5535 EXT.101 |